Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

On June 6, 2023 Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, reported Pedmarqsi– known as PEDMARK in the U.S. – was granted marketing authorization by the European Commission (Press release, Fennec Pharmaceuticals, JUN 6, 2023, View Source [SID1234632560]). Pedmarqsi is the first and only approved therapy in the EU for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumors. Further, Pedmarqsi was granted the marketing authorization under the paediatric-use marketing authorization (PUMA) which includes 8 years plus 2 years of data and market protection.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Today’s approval by the European Commission for Pedmarqsi to help reduce the risk of hearing loss is critical for the approximately four thousand children treated with cisplatin for solid tumors that have not spread," said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals. "Fennec is proud to bring this safe and effective therapy to the marketplace to mitigate the risk of permanent and irreversible bilateral hearing loss which occurs in approximately 60 percent of children treated with cisplatin and can be as high as 90 percent.i We look forward to making this important treatment available to the pediatric oncology community in the EU as soon as possible."

The European Commission granted marketing authorization approval to Pedmarqsi following the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) earlier this year. The CHMP’s decision was based on safety and efficacy data from two pivotal open-label, randomized Phase 3 trials (SIOPEL 6 and Clinical Oncology Group [COG] Protocol ACCL0431), which compared Pedmarqsi plus cisplatin-based regimen to cisplatin-based regimens alone for the reduction of cisplatin-induced hearing loss in pediatric patients.

The marketing authorization is applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein. PEDMARK was approved by the U.S. Food and Drug Administration (FDA) in September 2022.

About Cisplatin-Induced Ototoxicity

Cisplatin and other platinum compounds are essential chemotherapeutic agents for the treatment of many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity, or hearing loss, which is permanent, irreversible, and particularly harmful to the survivors of pediatric cancer.ii

The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.iii Infants and young children that are affected by ototoxicity at critical stages of development lack speech and language development and literacy, and older children and adolescents often lack social-emotional development and educational achievement.iv

PEDMARK (sodium thiosulfate)

PEDMARK is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients.7 PEDMARK is also the only therapeutic agent with proven efficacy and safety data with an established dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

In the U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.

PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Indications and Usage

PEDMARK (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Limitations of Use

The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

Important Safety Information

PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.

Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.

PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.

Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.

Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m2.

Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.

The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.

Please see full Prescribing Information for PEDMARK at: www.PEDMARK.com.

OSE Immunotherapeutics Presents Clinical Abstracts on Tedopi® at the ASCO 2023 Annual Meeting

On June 6, 2023 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reported a poster and a publication in abstract book featuring Tedopi, an immunotherapy activating tumor specific T-cells, in non-small cell lung cancer (NSCLC) and in ovarian cancer at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting held June 2 – 6 (Press release, OSE Immunotherapeutics, JUN 6, 2023, View Source [SID1234632542]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ADDITIONAL DATA FROM THE POSITIVE PHASE 3 CLINICAL TRIAL IN NSCLC, ATALANTE-1

The publication- abstract "# e21037", "Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial", reported an analysis performed to identify the prognostic factors of overall survival (OS) in each treatment group of the Phase 3 clinical trial of Tedopi (Atalante-1) in HLA-A2+ patients with advanced or metastatic non-small cell lung cancer (NSCLC), led by Pr. Benjamin Besse, Gustave Roussy cancer center, Principal Investigator of the study.

Tedopi is the first cancer vaccine that has shown positive and clinically meaningful efficacy results associated with a better safety and quality of life profile in monotherapy versus active comparator (chemotherapy-based standard of care) in third line with secondary resistance to immune checkpoint inhibitors in advanced or metastatic NSCLC (Phase 3 trial ATALANTE-1). Classical baseline factors (disease stage, histology) and treatment effect including best response, safety and ECOG* Performance Status (PS) deterioration were studied in this analysis and correlated to OS.

The analysis concludes that prognostic factors of OS differ between the cancer vaccine Tedopi and the standard chemotherapy treatment. The maintenance of a good ECOG PS was associated with longer survival for Tedopi, and the best response to treatment was the main prognostic factor for chemotherapy. These results support the mechanism of action of Tedopi in improving OS by controlling tumor growth regardless of best response.

Dr. Silvia Comis, Head of Clinical Development of OSE Immunotherapeutics, commented: "Following the positive results presented at the ASCO (Free ASCO Whitepaper) and ESMO (Free ESMO Whitepaper) 2022, these additional data showing how Tedopi improves OS strengthen the data basis to better understand the benefit of Tedopi on OS in NSCLC patients with secondary resistance to anti-PD-1 treatments. We look forward to advancing the clinical development of Tedopi in second line through a confirmatory pivotal Phase 3".

TEDOVA PHASE 2 CLINICAL TRIAL IN OVARIAN CANCER

The poster entitled, "TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope-based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum", presented by Dr. Alexandra Leary, from Gustave Roussy cancer center (Villejuif, France) and Principal Investigator of TEDOVA study, featured the ongoing Phase 2 international randomized open-label clinical trial, sponsored and conducted by ARCAGY-GINECO (Poster Bd # 310a).

Dr Alexandra Leary commented: "Our patients with ovarian cancer do not respond to checkpoint inhibitors alone as these tumors are ‘immune cold’, not likely to trigger a strong immune response and usually not responding to immunotherapy. The objective of TEDOVA is to turn ovarian cancer into an ‘immune hot’ tumor by using Tedopi, a combination of tumor associated neo-epitopes that have been optimized to break immunological self-tolerance. TEDOVA is the first trial evaluating such an innovative approach in ovarian cancer. We thank the international gynecological oncology community for their support and enthusiasm in promoting and conducting this research, moreover, helping to better understand this particularly aggressive disease."

* The ECOG score is a performance scale used to quantify the general health condition of a patient.
It is subdivided into 5 grades from 0 to 5, ranging from fully active (0) to fully disabled, then to death (5).

PRESENTATION DETAILS

"Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial." [NCT02654587]

Benjamin Besse, Paris-Saclay University, Institut Gustave Roussy, Villejuif, France

– Date: June 4, 8:00 – 11:00 am CET
– Abstract # e21037
– Session Type: Publication Only
– Session Title: Publication Only: Lung Cancer—Non-Small Cell Metastatic
– Track: Lung Cancer
– Sub Track: Non-Small Cell Lung Cancer – Advanced/Metastatic Disease

"TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope-based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum." [NCT04713514]

Alexandra Leary, Gustave-Roussy Cancer Campus, Villejuif, and GINECO, Paris, France

– Date: June 5, 1:15 – 4:15 pm CET
– Abstract # TPS5618
– Poster Bd # 310a
– Session Type: Poster Session
– Session Title: Gynecologic Cancer
– Track: Gynecologic Cancer
– Sub Track: Ovarian Cancer

ABOUT NON-SMALL CELL LUNG CANCER

Lung cancer is the leading cause of cancer mortality (18.0% of the total cancer deaths) with an estimated 2.2 million new cancer cases per year and with 1.8 million deaths. Lung cancer is the second most commonly diagnosed form of cancer after prostate cancer in men, and the third one in women, after breast and colorectal cancers. Among this population, 85% of lung cancer fall into the non-small cell lung cancer (NSCLC) form. About 58% are diagnosed at metastatic stage with a 5-year survival rate at 7%. Patients with HLA-A2 positive NSCLC represent 45% of this population. Over half of the patients will eventually develop secondary resistance to ICIs. Median overall survival after failure to immunotherapy is low with significant adverse events, thus a high unmet need for innovative therapeutic strategies to improve patient outcomes and enhance their quality of life. The targeted population for Tedopi in second line could be estimated up to 100,000 patients per year in 7 major markets across the US, Europe, China and Japan.

ABOUT OVARIAN CANCER

Worldwide, ovarian cancer is the seventh most common cancer and the eighth leading cause of cancer death in women. The five-year survival rate for ovarian cancer worldwide is 30-40%. In 2020, there were nearly 313,000 new cases diagnosed*. Once the first relapse has occurred, ovarian cancer is managed as a chronic disease, requiring iterative lines of platinum-based chemotherapy. After 6 cycles, chemotherapy is stopped and one of the major priorities is to extend "chemotherapy-free" intervals for the patients by proposing maintenance strategies with targeted therapies (PARP inhibitors or bevacizumab). By the time patients with ovarian cancer present with first or second relapse, they will have received BOTH a PARP inhibitor and bevacizumab, thus patients progressing post-PARP inhibitors and bevacizumab represent an area of unmet medical need, they are offered chemotherapy alone with no maintenance strategy. The TEDOVA trial adresses these women.

Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors

On June 6, 2023 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, reported that data from the ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), were published in Nature Medicine (Press release, Repare Therapeutics, JUN 6, 2023, View Source [SID1234632541]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The article, entitled "Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results" can be accessed here.

"The results of the TRESR trial demonstrate not only the single agent activity of camonsertib, a potent and selective ATR inhibitor, but also define the importance of enhanced precision medicine approaches, such as the identification of bi-allelic alterations affecting the target DNA repair genes and other biomarkers, as well as the use of longitudinal liquid biopsies to guide its delivery to the right patients," said Maria Koehler, MD, PhD, EVP and Chief Medical Officer of Repare. "This study provides a framework for the testing of novel therapeutic approaches based on the principles of synthetic lethality and informed by genome-wide CRISPR screens."

TRESR (NCT04497116) is a first-in-human, multi-center, open-label Phase 1/2 dose-escalation and expansion study, designed to establish the recommended Phase 2 dose and schedule, evaluate safety and pharmacokinetics and identify preliminary anti-tumor activity associated with camonsertib, given alone and in combination with talazoparib or in combination with gemcitabine. Clinical data were most recently presented at the 2022 and the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meetings, demonstrating the promising safety and efficacy profile of camonsertib, both as a monotherapy and in combination with a poly (ADP-ribose) polymerase inhibitor.

BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme

On June 6, 2023 BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, reported that patients have been initially dosed in its Phase 2 trial for BPM 31510 for Glioblastoma Multiforme (GBM), a fast-growing and aggressive form of brain cancer (Press release, BPGbio, JUN 6, 2023, View Source [SID1234632540]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BPM 31510, the company’s lead drug candidate, acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death. BPM 31510 for GBM is one of the three oncology drug assets in clinical phase that BPGbio developed on its AI-driven Interrogative Biology platform.

GBM is one of the most aggressive forms of brain cancer with survival times averaging only 15-18 months from diagnosis, the 5 year survival rate is under 10 percent. There are approximately 13,000 new cases of GBM-related tumors annually in the US, occuring more frequently in patients over 60.

In preclinical studies in orthotopic models of GBM, pre-treatment with BPM 31510 followed by radiation therapy was associated with significant long-term survival compared to radiation alone, while BPM 31510 showed an anti-cancer effect in GBM patients without damaging normal brain cells. A Phase 1 trial in advanced, refractory GBM patients completed at Stanford Medicine demonstrated a favorable safety profile of BPM 31510, supporting Phase 2 trial advancement.

"This milestone is a testament to the value of our Interrogative Biology platform and its capability to develop drugs for the treatment of deadly diseases where patients desperately need better therapeutics," said Niven R. Narain, Ph.D., President and CEO of BPGbio. "Advancing this candidate into Phase 2 human trials is a big step of progress for both the company and patients suffering from GBM."

The open-label, multi-cohort Phase 2 study for BPM 31510 for treatment of GBM is led by Seema Nagpal, MD, Clinical Associate Professor, Division of Neuro-Oncology at Stanford Medicine. The study will include planned interim analyses primary, secondary and exploratory endpoints. Current clinical sites include lead site Stanford Medicine, Cedars-Sinai Medical Center in Los Angeles and Mt. Sinai Medical Center in New York. Additional sites are currently being assessed in the United States and the United Kingdom.

"The combined preclinical and phase 1 safety and tolerability data provided valuable insights into treatments for Glioblastoma Multiforme. Leveraging the results from the phase 1 clinical trial, we are looking forward to further advance our discoveries using neoadjuvant BPM 31510 in phase 2," said Seema Nagpal, MD.

Amphera Announces a Positive Opinion of the European Medicines Agency on the Granting of Orphan Medicinal Product Designation for MesoPher in Pancreatic Cancer

On June 6, 2023 Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, reported that the EMA Committee for Orphan Medicinal Products (COMP) has recommended the granting of orphan medicinal product designation for MesoPher in pancreatic cancer (Press release, Amphera, JUN 6, 2023, View Source [SID1234632539]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines. PheraLys contains a broad repertoire of tumour-associated antigens, many of which are present in pancreatic cancer and other cancers.

In December 20221, Amphera reported topline results from the phase II REACTIVE trial in patients with resected pancreatic cancer. MesoPher demonstrated a statistically significant 2-year Recurrence Free Survival of 60% and an excellent safety profile.

1) View Source

Notes to Editors

About EMA Orphan Designation

Source: View Source

"The EU offers incentives to encourage companies to research and develop medicines for rare diseases that otherwise would not be developed. To access these incentives, companies can apply for orphan designation for their medicine, provided certain criteria are met.

Criteria for orphan designation:

The medicine must treat, prevent, or diagnose a disease which is life-threatening or chronically debilitating, or it is unlikely that the medicine will generate sufficient returns to justify the investment needed for its development
The disease must not affect more than 5 in 10,000 people across the EU
No satisfactory method of diagnosis, prevention or treatment exists, or if such a method already exists, the medicine must be of significant additional benefit to those affected by the condition
During an orphan medicine’s research and development, the company can benefit from incentives such as scientific advice on study protocols, various fee reductions and access to EU grants. Orphan-designated medicines that eventually make it to the market, and for which it can be demonstrated that they maintain the criteria for the designation, are granted 10 years of market exclusivity.

Orphan designation is not an authorization: Not all orphan-designated medicines reach the marketing authorisation application stage. Those that do, are evaluated by EMA’s Committee for Medicinal Products for Human Use (CHMP) using the same strict safety and efficacy standards that apply to all medicines evaluated by EMA.